Merck
CN
HomeWebinarsSustainable Alternatives to Triton™ X-100 for Biomanufacturing, the Deviron® Portfolio

Sustainable Alternatives to Triton™ X-100 for Biomanufacturing, the Deviron® Portfolio



WEBINAR

Detergents are employed in various steps of biomanufacturing. Up to now, Triton™ X-100 has been the most used detergent. However, one of its degradation products, 4-tert-octylphenol, is an endocrine disruptor and very dangerous for the environment. Triton™ X-100 has been prohibited in the EU since 2021. The biotherapeutic industry together is faced with the challenges of identifying, producing, and implementing new alternatives. We will show to you the features and the application data of our portfolio of sustainable and biodegradable alternatives to Triton™ X-100, the Deviron® detergents.

In this webinar, you will learn:

  • Why Triton™ X-100 is banned in the EU 
  • That the Deviron® portfolio offers sustainable alternatives for biomanufacturing 
  • About the application results for various biopharma utilizations that are available
  • How downstream removal strategies were developed

Speakers

Alice Antonello, Ph.D.

Alice Antonello, Ph.D.

Merck

Senior Scientist - Bioprocess Chemistry

Alice Antonello is senior scientist in the bioprocess chemistry team in process and formulation materials - technology and innovation at Merck. She is mainly focused on the development and application of surfactants for bioprocessing, from cell cultivation to harvest and first treatments of the product. She holds a Ph.D. in Chemistry from Max Planck Institute for Polymer Research in Mainz.

Sarah Lechat

Sarah Lechat

Merck

Global Strategic Marketing Manager

Sarah is a global strategic marketing manager for Merck, specializing in manufacturing enzymes and downstream chemicals. She uses her expertise serving novel modalities markets (VGT, mRNA, …) and bringing to life new innovative solutions to meet their manufacturing needs. She has worked in the pharmaceutical industry for more than 10 years and has held a number of roles in this capacity worldwide, including bioproduct development & regulatory consultancy for exporting biotech companies.

Sarah holds a master's degree in molecular & cell biology (specializing in cell & gene therapy) from the UPMC and Ecole Normale Supérieure de Paris. She also holds a master's degree in health marketing & market access from the Sorbonne University.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?